Clinical trial
Irinotecan, Gemcitabine and Radiation Therapy for Pancreatic Cancer
NCT00192712 · Rambam Health Care Campus, Other · Completed
Key facts
| NCT number | NCT00192712 |
|---|---|
| Title | Irinotecan, Gemcitabine and Radiation Therapy for Pancreatic Cancer |
| Official title | Phase II Study of Irinotecan and Gemcitabine (IrinoGem) Combined With 3-D Conformal Radiation Therapy for Locally Advanced Pancreatic Cancer |
| Lead sponsor | Rambam Health Care Campus, Other |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | irinotecan, gemcitabine |
| Enrollment | 20 |
| Start date | Nov 1, 2002 |
| Completion | Sep 1, 2010 |
| First posted | Sep 19, 2005 |
| Last update posted | Nov 10, 2010 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: